How to cite item

Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver

  
@article{JGO14851,
	author = {Kelly P. Orwat and Thomas H. Beckham and Samuel Lewis Cooper and Michael S. Ashenafi and Michael Bret Anderson and Marcelo Guimaraes and Ricardo Yamada and David T. Marshall},
	title = {Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver},
	journal = {Journal of Gastrointestinal Oncology},
	volume = {0},
	number = {0},
	year = {2017},
	keywords = {},
	abstract = {Background: Hepatic malignancies are common including primary malignancies and metastases. Transarterial radioembolization (TARE) is an important treatment option. We reviewed safety and efficacy of (TARE) in our patients to identify factors that may impact treatment outcomes in a heterogeneous population. 
Methods: All patients that received TARE at the Medical University of South Carolina from March 2006 through May of 2014 were included. Kaplan-Meier estimates on overall survival (OS) from date of first procedure are reported. Potential prognostic factors for OS were evaluated using log rank tests and Cox proportional hazards models. 
Results: In the 114 patients that received TARE at our institution, median follow-up was 6.4 months (range, 0–86 months) with the following histologies: colorectal (CR) n=55, hepatocellular (HC) n=20, cholangiocarcinoma (CC) n=16, neuroendocrine (NE) n=12, breast (BR) n=6, other n=5. At least 1 line of prior systemic therapy was noted in 79% of patients. Median OS was significantly better with NE and BR histology, and in those with normal albumin levels. With an albumin >3.4 median OS was 10.3 months, but was only 3.1 months with an albumin },
	issn = {2219-679X},	url = {http://jgo.amegroups.com/article/view/14851}
}